retatrutide clinical trials safety efficacy and of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled Retatrutide FDA Approval Status 2026:

SURMOUNT-3 and -4: demonstrated continued weight loss with sustained treatment, and significant regain when medication was stopped supporting ongoing use

177 kept tumor animals in very low blood sugar content in insulin convulsions for hours

Gallbladder and Biliary Effects: A Murky Link GLP-1s slow gastric emptying, which helps with satietybut may also play a role in gallbladder issues

doi: 10.1038/nrc1074 254 LortholaryO.ObengaG.BiswasP.CaillotD.ChachatyE.BienvenuA

When applied topically, it helps stimulate collagen and elastin, promote skin regeneration, and visibly improve tone and texture

GLP-1 agonists are large peptide molecules